

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Claim 1 (currently amended): A pharmaceutical composition comprising an active agent having low water solubility encapsulated in nanoparticles comprising a pharmaceutically acceptable polymer ~~solubilizing agent~~ and dispersed in an aqueous formulation base, said aqueous formulation base further comprising polyvinyl alcohol; and wherein said ~~solubilizing agent~~ is a pharmaceutically acceptable polymer, which is resistant to gastric juices and soluble in intestinal juices, is chosen from at least one of ~~(i) a copolymer selected from the group consisting of (a) methacrylic acid or acrylic acid and (b) methyl or ethyl esters of acrylic or methacrylic acid monomers, [(ii)]~~ polyvinyl acetate phthalate (PVAP), ~~[(iii)]~~ hydroxypropyl methyl cellulose acetate succinate (HPMCAS), ~~[(iv)]~~ hydroxypropyl methyl cellulose phthalate (HPMCP), ~~[(v)]~~ cellulose acetate phthalate (CAP) and ~~[(vi)]~~ cellulose acetate trimillitate (CAT); and wherein said pharmaceutical composition is an oral dosage form.

Claim 2 to 31 (cancelled)

Claim 32 (previously presented): A pharmaceutical composition according to claim 1, wherein said active agent is selected from the group consisting of immuno-suppressive agents, non-steroidal anti-inflammatory agents, calcium channel blockers, immunomodulators, and antibiotic agents.

Claim 33 (cancelled)

Claim 34 (new): A pharmaceutical composition according to claim 1, wherein said nanoparticles are nanospheres.

Claim 35 (new): A pharmaceutical composition according to claim 1, wherein said active agent has a water solubility of less than 500 mg/1000 ml.

Claim 36 (new): A pharmaceutical composition according to claim 35, wherein said water solubility is less than 200 mg/1000 ml.

Claim 37 (new): A pharmaceutical composition according to claim 1, wherein said nanoparticles range in a size from about 10 to 1000 nm.